- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.06. | Guard Therapeutics International AB: Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study | 91 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company's ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective... ► Artikel lesen | |
| 27.05. | Guard Therapeutics International AB: Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study | 104 | GlobeNewswire (Europe) | Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial... ► Artikel lesen | |
| 25.03. | Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study | 260 | GlobeNewswire (Europe) | Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled... ► Artikel lesen | |
| 14.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025 | 1.366 | Xetra Newsboard | Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen | |
| 10.03. | Guard Therapeutics International AB: The Board of Directors of Guard Therapeutics has resolved on a previously announced rights issue of approximately SEK 150 million | 232 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 27.02. | Guard Therapeutics International AB: Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study | 145 | GlobeNewswire (Europe) | Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study... ► Artikel lesen | |
| 04.09.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Guard Therapeutics International AB | 411 | GlobeNewswire | With effect from September 05, 2024, the subscription rights in Guard
Therapeutics International AB will be traded on First North Growth Market.
Trading will continue up until and including September... ► Artikel lesen | |
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 02.09.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024 | 608 | Xetra Newsboard | Das Instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024 The instrument MSPA MA0000011488 ITISSALAT AL-MA.... ► Artikel lesen | |
| 29.08.24 | Guard Therapeutics International AB: First patient dosed in Guard Therapeutics' phase 2b study POINTER | 256 | GlobeNewswire (Europe) | Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
"It... ► Artikel lesen | |
| 27.08.24 | Guard Therapeutics International AB: Guard Therapeutics carries out announced rights issue (repair issue) | 219 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 60,46 | +0,63 % | Novonesis (Novozymes A/S): Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe | Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
A new report reveals that biosolutions could generate EUR 133 billion in economic gains and... ► Artikel lesen | |
| GENMAB | 191,15 | +0,16 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,658 | -0,82 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships | ||
| VERICEL | 30,600 | +0,66 % | Vericel Corporation: Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025 | ||
| SENSEI BIOTHERAPEUTICS | 2,813 | -100,00 % | XFRA FA20,0RA0,4070: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFORWARD AIR CORP.... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,474 | -9,89 % | MustGrow Biologics Corp. Announces Results of Shareholder Meeting | Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,360 | -100,00 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| REGENXBIO | 7,250 | +2,84 % | REGENXBIO Inc.: REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy | Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking... ► Artikel lesen | |
| AKEBIA | 3,384 | +1,99 % | Akebia auf H.C. Wainwright Konferenz: Strategische Einblicke in Nierenmedikamente | ||
| FENNEC PHARMACEUTICALS | 7,350 | +0,68 % | Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 10,700 | +2,88 % | Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism | CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 07.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.02.2025ISIN NameCA09226M1005 BLACK... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 3,710 | +1,09 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis | SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 10,300 | -6,36 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen |
Das Unternehmen GUARD THERAPEUTICS INTERNATIONAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,73 % bei einem Aktienkurs von 1,695 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.